Literature DB >> 23000312

Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase.

Federica Braga1, Simona Ferraro, Roberta Mozzi, Alberto Dolci, Mauro Panteghini.   

Abstract

OBJECTIVES: Chromogranin A (CgA) and neuron-specific enolase (NSE) are biomarkers for neuroendocrine tumors. Although the knowledge of their biological variation (BV) is critical, only one study for CgA and no data for NSE are available. We report a definitive assessment of BV components of these biomarkers in the same cohort of subjects by an accurately experimental protocol. DESIGN AND METHODS: We collected five blood specimens from each of 22 healthy volunteers (10 men and 12 women, 23-54 years) on the same day every two weeks for two months. Serum specimens were stored at -80 °C until analysis and analyzed in a single run in duplicate. Data were analyzed by ANOVA.
RESULTS: Serum CgA concentrations were significantly higher for women than for men (P=0.01), whereas no difference was found for NSE. Intra-individual variance was not different between genders for both biomarkers. Within- and between-subject CVs were 16.3% and 33.5% for CgA and 13.6% and 11.5% for NSE, respectively. CgA showed marked individuality, suggesting that the use of population-based reference limits is inadequate for its interpretation. Conversely, the low individuality of NSE allows the use of a single reference interval. Reference change values were 46% for CgA and 39% for NSE. Desirable analytical goals for imprecision, bias, and total error were <8.2%, ±9.3%, and ±22.8% for CgA, and <6.8%, ±4.5%, and ±15.7% for NSE, respectively.
CONCLUSION: In this study, we defined BV components of serum CgA and NSE and derived indices that may improve the clinical use of these biomarkers.
Copyright © 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23000312     DOI: 10.1016/j.clinbiochem.2012.09.005

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  8 in total

1.  Biological variation of serum neuron-specific enolase and carbohydrate antigen 724 tumor markers.

Authors:  Shuo Wang; Min Zhao; Runqing Mu; Xin Zhang; Ke Yun; Hong Shang
Journal:  J Clin Lab Anal       Date:  2017-09-19       Impact factor: 2.352

2.  Biological Variation and Reference Change Value Data for Serum Neuron-Specific Enolase in a Turkish Population.

Authors:  Selcuk Matyar; Ozlem Goruroglu Ozturk; Esin Ziyanoglu Karacor; Sedefgul Yuzbasioglu Ariyurek; Gulhan Sahin; Filiz Kibar; Akgun Yaman; Tamer Inal
Journal:  J Clin Lab Anal       Date:  2016-04-28       Impact factor: 2.352

3.  Preoperative serum chromogranin-a is predictive of survival in locoregional jejuno-ileal small bowel neuroendocrine tumors.

Authors:  Praveen D Chatani; John G Aversa; James D McDonald; Tahsin M Khan; Xavier M Keutgen; Naris Nilubol
Journal:  Surgery       Date:  2021-04-02       Impact factor: 4.348

4.  Evaluation of a new immunoassay for chromogranin A measurement on the Kryptor system.

Authors:  R H P van der Knaap; D J Kwekkeboom; C R B Ramakers; Y B de Rijke
Journal:  Pract Lab Med       Date:  2015-03-10

5.  The paracrine induction of prostate cancer progression by caveolin-1.

Authors:  Chun-Jung Lin; Eun-Jin Yun; U-Ging Lo; Yu-Ling Tai; Su Deng; Elizabeth Hernandez; Andrew Dang; Yu-An Chen; Debabrata Saha; Ping Mu; Ho Lin; Tsai-Kun Li; Tang-Long Shen; Chih-Ho Lai; Jer-Tsong Hsieh
Journal:  Cell Death Dis       Date:  2019-11-04       Impact factor: 8.469

6.  Identification of a Glycosyltransferase Signature for Predicting Prognosis and Immune Microenvironment in Neuroblastoma.

Authors:  Yongliang Sha; Lei Han; Bei Sun; Qiang Zhao
Journal:  Front Cell Dev Biol       Date:  2022-01-06

7.  Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy.

Authors:  Jaume Capdevila; Enrique Grande; Rocío García-Carbonero; Marc Simó; Mª Isabel Del Olmo-García; Paula Jiménez-Fonseca; Alberto Carmona-Bayonas; Virginia Pubul
Journal:  Oncologist       Date:  2022-04-05

8.  A novel bioengineered fragment peptide of Vasostatin-1 exerts smooth muscle pharmacological activities and anti-angiogenic effects via blocking VEGFR signalling pathway.

Authors:  Ran Wei; Qiushuang Wu; Nana Ai; Lei Wang; Mei Zhou; Chris Shaw; Tianbao Chen; Richard Dequan Ye; Wei Ge; Shirley W I Siu; Hang Fai Kwok
Journal:  Comput Struct Biotechnol J       Date:  2021-05-03       Impact factor: 7.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.